THALIDOMIDE
Thalidomide is an immunomodulatory and antiangiogenic agent used for multiple myeloma and erythema nodosum leprosum. It reduces TNF and modulates Tcell responses. Side effects include severe teratogenicity, neuropathy, sedation, constipation, thrombosis, and rash, requiring strict monitoring. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
THALIDOMIDE demonstrates a broad and highly integrated biochemical activity architecture involving multiaxis signalling interference, mitochondrial-network recalibration, catalyticdomain modulation, cytoskeletal restructuring, redoxequilibrium shaping, ionflux redistribution and transcriptionfactor pathway realignment. Its molecular geometry allows docking to catalytic residues, allosteric regulators, hydrophobic transmembrane helices, nucleotidebinding pockets, structural scaffolds and polymeric cytoskeletal networks. This enables THALIDOMIDE to influence metabolic, structural, genomic, electrophysiological and stressadaptive systems simultaneously.
THALIDOMIDE may modulate phosphorylation gradients, modify ERK/JNK/MAPK propagation speeds, influence PI3KAKT survival bias, shift Gprotein signalling states, control Ca²⁺ microdomain behaviour, alter IP/DAG cascades, and recalibrate cAMPPKA pathway amplitude. Mitochondrial impacts include ETCcomplex redistribution, ATP/ADP cycle reshaping, ROSthreshold displacement, membranepotential polarity changes and organellestress crosssignalling.
HighPrecision
- Ultrascale kinome disruption & catalyticcascade modelling
- Molecular docking & conformationalflow prediction
- UPR/ERstress and mitophagy/autophagy integration research
- Fullspectrum multiomics reconstruction (RNAseq, metabolomics, phosphoproteomics)
- Advanced cytoskeletal forcedistribution & polymerturnover analysis
- Cellfate simulation across apoptosis, ferroptosis, necroptosis & parthanatos
- AIenhanced SAR/QSAR simulation for molecular optimisation
Toxicodynamics & Hazard Spectrum
- Rapid ROS escalation & antioxidantbuffer collapse
- Mitochondrial fragmentation or ETC suppression
- Severe Ca²⁺/Na⁺/K⁺ ionflux destabilisation
- Cytoskeletal polymer breakdown & structuralintegrity failure
- Membrane rupture & lipidbilayer thinning
- Overactivation of inflammatory cascades (NF-κB, STAT, IRF)
- Activation of multiple programmed-cell-death pathways
- Epigenetic drift including methylation instability
For expert not intended for biological exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C13H10N2O4 |
|---|---|
| Molecular Weight | 258.23 g/mol |
| CAS Number | 50-35-1 |
| Storage Condition | Commercially available thalidomide capsules should be stored at 15-30 °C and protected from light. |
| Solubility | less than 1 mg/mL at 72 °F (NTP, 1992) |
| Purity | Purity information is available upon request (COA). |
| Synonym | thalidomide; 50-35-1; Thalomid; Contergan; Pantosediv |
| IUPAC/Chemical Name | 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| InChl Key | UEJJHQNACJXSKW-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
